Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indicesIngeborg M. Bajema, Agnes B. Fogo, Suzanne Wilhelmus et al.|Kidney International|2018Cited by 1k
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialBrad H. Rovin, Catarina Almeida, Jonathan Barratt et al.|The Lancet|2023Cited by 264
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceCharles R. Swanepoel, Martin Zeier, Mohamed G. Atta et al.|Kidney International|2018Cited by 244
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trialHiddo J.L. Heerspink, Toby Coates, Jai Radhakrishnan et al.|The Lancet|2023Cited by 214
Rationale and design of the Kidney Precision Medicine ProjectIan H. de Boer, Jonathan Himmelfarb, Nir Hacohen et al.|Kidney International|2021Cited by 187